Analysed ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) News Sources
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
29-03-2026
yahoo.com
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy
29-03-2026
yahoo.com
Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids
27-03-2026
marketbeat.com
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
27-03-2026
proactiveinvestors.com
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investor Concerns Linger Amid Middle East Conflict
27-03-2026
yahoo.com
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
27-03-2026
yahoo.com
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances
03-03-2026
proactiveinvestors.com
What is the current price of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)?
The current price of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) is $3.49.
ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) since the previous trading day is $-0.11.
ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) since the previous trading day is -3.0556%.
What is the most recent average sentiment score for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)?
The most recent average sentiment score for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)?
The most recent sentiment for ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ) is .
SEC-8K** Filing Available For ROCKET PHARMACEUTICALS INC (RCKT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.